Finance

Lists
Why is 524494 down 3,51%?
Dive Deeper
524494:BOM
IPCA Laboratories Ltd
1 845,00 INR
-3,51%
(-67,20) 1D
16 ოქტ, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 524494...
Open
1 913,95 INR
High
1 913,95 INR
Low
1 812,60 INR
Mkt. cap
468,21 მლრ.
Avg. vol.
27,90 ათ.
Volume
12,00 ათ.
Dividend
0,33%
Quarterly dividend
1,50 INR
Ex-dividend date
7 აგვ. 2026
P/E ratio
35,74
52-wk high
2 039,30 INR
52-wk low
1 252,95 INR
EPS
51,63 INR
Shares outstanding
126,35 მლნ.
No. of employees
17 ათ.
Open
1 913,95 INR
High
1 913,95 INR
Low
1 812,60 INR
Mkt. cap
468,21 მლრ.
Avg. vol.
27,90 ათ.
Volume
12,00 ათ.
Dividend
0,33%
Quarterly dividend
1,50 INR
Ex-dividend date
7 აგვ. 2026
P/E ratio
35,74
52-wk high
2 039,30 INR
52-wk low
1 252,95 INR
EPS
51,63 INR
Shares outstanding
126,35 მლნ.
No. of employees
17 ათ.
News stories
From web sources and news partners
Profile
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The company manufactures and markets more than 350 finished-dosage formulations and around 80 active pharmaceutical ingredients, covering therapeutic areas that include pain management, rheumatology, antimalarials, cardiovascular medicine, dermatology and anti-diabetics, and has an emerging biosimilars business. Its products are sold in over 100 countries, and it is one of India's larger API exporters, supplying more than 70 countries. Ipca is one of the largest global suppliers of the antimalarials hydroxychloroquine and chloroquine, as well as of APIs such as atenolol, chlorthalidone, losartan and metoprolol. Since 2023, it has held a majority stake in Unichem Laboratories. The company is listed on the BSE and the National Stock Exchange of India, and reported consolidated revenue of ₹9,646 crore in the financial year ended 31 March 2026. Wikipedia
About IPCA Laboratories Ltd
CEO-
Employees17,2 ათ.
Founded19 ოქტ. 1949
Headquarters-
SectorPharmaceutical industry
Websiteipca.com
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
25,56 მლრდ.
23,92 მლრდ.
23,89 მლრდ.
27,88 მლრდ.
Cost of goods sold
7,82 მლრდ.
6,58 მლრდ.
10,31 მლრდ.
7,97 მლრდ.
Cost of revenue
7,82 მლრდ.
6,58 მლრდ.
10,31 მლრდ.
7,97 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,38 მლრდ.
5,46 მლრდ.
5,54 მლრდ.
6,02 მლრდ.
Operating expense
13,33 მლრდ.
13,09 მლრდ.
9,17 მლრდ.
14,32 მლრდ.
Total operating expenses
21,15 მლრდ.
19,67 მლრდ.
19,48 მლრდ.
22,29 მლრდ.
Operating income
4,42 მლრდ.
4,26 მლრდ.
4,41 მლრდ.
5,59 მლრდ.
Other non operating income
278,60 მლნ.
201,90 მლნ.
-680,30 მლნ.
252,60 მლნ.
EBT including unusual items
3,89 მლრდ.
4,46 მლრდ.
4,02 მლრდ.
5,74 მლრდ.
EBT excluding unusual items
4,47 მლრდ.
4,28 მლრდ.
3,62 მლრდ.
5,74 მლრდ.
Income tax expense
1,08 მლრდ.
819,30 მლნ.
950,50 მლნ.
1,49 მლრდ.
Effective tax rate
27,81%
18,39%
23,66%
26,03%
Other operating expenses
6,92 მლრდ.
6,55 მლრდ.
2,56 მლრდ.
7,20 მლრდ.
Net income
2,83 მლრდ.
3,26 მლრდ.
2,99 მლრდ.
4,02 მლრდ.
Net profit margin
11,05%
13,64%
12,52%
14,41%
Earnings per share
12,35
12,09
13,31
15,84
Interest and investment income
-
-
317,20 მლნ.
-
Interest expense
-196,10 მლნ.
-176,20 მლნ.
-199,90 მლნ.
-118,80 მლნ.
Net interest expenses
-196,10 მლნ.
-176,20 მლნ.
117,30 მლნ.
-118,80 მლნ.
Depreciation and amortization charges
1,03 მლრდ.
1,08 მლრდ.
1,04 მლრდ.
1,11 მლრდ.
EBITDA
5,43 მლრდ.
5,18 მლრდ.
5,37 მლრდ.
6,55 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები